Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Mol Cancer Res. 2017 Aug 1;15(11):1608–1622. doi: 10.1158/1541-7786.MCR-17-0188

Figure 2. ADAM12 expression is upregulated in activated endothelial cells and stimulates cell migration and tube-formation.

Figure 2

ADAM12-L transcript (A, B) and protein (immunostaining; C) was higher in HMVECs in response to treatment with bFGF (50ng/ml) and VEGF (100ng/ml) or cytokines like TNFα (5ng/ml), TGFβ-1 (5ng/ml) or IL-1α (1ng/ml). Treatment with angiogenic factors or cytokines resulted in 5–10-fold increase in ADAM12 in the CM (D; top), and lysates (D; bottom). Realtime RT-PCR and ELISA results are an average of 3 and 2 independent experiments respectively. Migration of ADAM12-L and ADAM12-S-expressing HUVECs was significantly higher than vector-transfected cells (E). Tube-formation of EC was significantly increased in ADAM12-expressing cells compared to controls (F). The effect of exogenous recombinant ADAM12-S on migration and tube-formation in EC (G,H) (average of 3 independent experiments, one way ANOVA; *P<0.05, **P<0.00001).